SCHEMBL4273254

SCHEMBL4273254

CCCCCCCCCCCCCC(=O)OC1CCCn2c1nc(C)c(CCN1CCC(c3noc4cc(F)ccc34)CC1)c2=O

nearest known ligand 0.71

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
DRD2 P14416 12/20 0.71
HTR2A P28223 11/20 0.71
HTR7 P34969 4/20 0.71
KCNH2 Q12809 4/20 0.71
ADRA2A P08913 2/20 0.71
ADRA2B P18089 2/20 0.71
ADRA2C P18825 2/20 0.71
DRD1 P21728 2/20 0.71
DRD4 P21917 2/20 0.71
DRD5 P21918 2/20 0.71
HTR1D P28221 2/20 0.71
HTR1B P28222 2/20 0.71
HTR2C P28335 2/20 0.71
ADRA1A P35348 2/20 0.71
HRH1 P35367 2/20 0.71
DRD3 P35462 2/20 0.71
SCN5A Q14524 2/20 0.71
KCND3 Q9UK17 1/20 0.71
ACHE P22303 3/20 0.62
SLC6A4 P31645 2/20 0.62

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7343354 1.00 DRD2 (0.71) DRD2HTR2AHTR7KCNH2ADRA2A
Paliperidone Palmitate SCHEMBL1871384 1.00 DRD2 (0.71) DRD2HTR2AHTR7KCNH2ADRA2A
Paliperidone Palmitate SCHEMBL12415674 1.00 DRD2 (0.71) DRD2HTR2AHTR7KCNH2ADRA2A
SCHEMBL4263975 1.00 DRD2 (0.71) DRD2HTR2AHTR7KCNH2ADRA2A
Paliperidone Palmitate SCHEMBL18131955 1.00 DRD2 (0.71) DRD2HTR2AHTR7KCNH2ADRA2A
SCHEMBL24018542 1.00 DRD2 (0.71) DRD2HTR2AHTR7KCNH2ADRA2A
Hydrochloric Acid SCHEMBL9196896 0.99 DRD2 (0.70) DRD2HTR2AHTR7KCNH2ADRA2A
SCHEMBL14378106 0.96 DRD2 (0.66) DRD2HTR2AHTR7KCNH2ADRA2A
SCHEMBL24465197 0.96 DRD2 (0.66) DRD2HTR2AHTR7KCNH2ADRA2A
SCHEMBL22633922 0.95 HTR2A (0.71) DRD2HTR2AHTR7KCNH2ADRA2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2009089076-A2 PROCESSES FOR THE PREPARATION AND PURIFICATION OF PALIPERIDONE PALMITATE TEVA PHARMACEUTICAL INDUSTRIES LTD. (IL) 2009-07-16 WO claimed
US-20090209757-A1 Processes for the preparation and purification of paliperidone palmitate TEVA PHARMACEUTICALS USA, INC. 2009-08-20 US disclosed
US-20090209757-A1 Processes for the preparation and purification of paliperidone palmitate TEVA PHARMACEUTICALS USA, INC. 2009-08-20 US disclosed
WO-2009089076-A2 PROCESSES FOR THE PREPARATION AND PURIFICATION OF PALIPERIDONE PALMITATE TEVA PHARMACEUTICAL INDUSTRIES LTD. (IL) 2009-07-16 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090209757-A1 Processes for the preparation and purification of paliperidone palmitate GLP1R, DPP4, ADCYAP1R1 DRD2 651/4885HTR2A 374/4885HTR7 533/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.